A new glucagon-like peptide-1 analogues-Semaglutide
10.13699/j.cnki.1001-6821.2018.20.018
- VernacularTitle:新型胰高血糖素样肽-1类似物—索马鲁肽
- Author:
Xin-Li ZHANG
1
;
Fa-Ming DING
;
Mao-Shan YIN
Author Information
1. 青岛市黄岛区中心医院
- Keywords:
Semaglutide;
type 2 diabetes mellitus;
glucagon-like peptide-1
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(20):2456-2460
- CountryChina
- Language:Chinese
-
Abstract:
The glucagon-like peptide-1 (GLP-1) receptor agonist has been a well-received peptide product in the field of diabetes treatment .Semaglutide is a long-term GLP -1 agent, approved in December, 2017 by US Food and Drug Admins-tration(FDA).This article reviewed the pharmaceutical information , pharmacology and toxicology and clinical trial data of somaglutide , and commented on its efficacy and safety specially.We hope to provide reference for doctors and patients .
